CLDI · Calidi Biotherapeutics Inc
United States · RS rating 26 · As of 2026-11-03
| Price | 0.75 USD |
|---|---|
| 1-day change | +13.8% |
| RS rating (overall / 1M / 3M / 12M) | 26 / 13 / 7 / 21 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 22 / 19 / 39 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +57.3% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +60.4% |
| Market cap (USD) | $2.4M |